# US 2003/0204072 A1 · Protein tyrosine kinases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0204072 A1
- Document ID: US20030204072A1
- Status: Published application
- Kind: A1
- Application number: 09/236,939
- Filed: 1999-01-25
- Published: 2003-10-30
- Earliest claimed: 1993-11-23
- Inventors: PAUL J. GODOWSKI; MELANIE R. MARK; DAVID T. SCADDEN; KEVIN P. BAKER; WILL F. BARON
- Web page: https://patentgrep.com/patent/US20030204072A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/71: for growth factors; for growth regulators
- C07K 14/715: for cytokines; for lymphokines; for interferons
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- C12Q 1/485: {involving kinase}
- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/573: for enzymes or isoenzymes
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N 2333/912: transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N 2333/9121: with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N 2500/00: Screening for compounds of potential therapeutic value
- Y10S 435/975: Kit
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.

## Claims

### Claim 1

Isolated Rse or HPTK6 receptor protein tyrosine kinase (rPTK).

### Claim 2 (depends on 1)

The Rse rPTK of claim 1, wherein the Rse rPTK is antigenically active.

### Claim 3 (depends on 1)

The Rse rPTK of claim 1, wherein the Rse rPTK is biologically active.

### Claim 4 (depends on 1)

The Rse rPTK of claim 1 sharing at least 80% sequence identity with the translated Rse sequence shown in FIG. 1A.

### Claim 5 (depends on 4)

The Rse rPTK of claim 4 sharing at least 90% sequence identity with the translated Rse sequence shown in FIG. 1A.

### Claim 6 (depends on 1)

The HPTK6 rPTK of claim 1, wherein the HPTK6 rPTK is antigenically active.

### Claim 7 (depends on 1)

The HPTK6 rPTK of claim 1, wherein the HPTK6 rPTK is biologically active.

### Claim 8 (depends on 1)

The HPTK6 rPTK of claim 1 sharing at least 80% sequence identity with the translated HPTK6 sequence shown in FIG. 2.

### Claim 9 (depends on 8)

The HPTK6 rPTK of claim 8 sharing at least 90% sequence identity with the translated HPTK6 sequence shown in FIG. 2.

### Claim 10

An isolated receptor protein tyrosine kinase comprising an amino acid sequence selected from the group consisting of:
the amino acid sequence shown in FIG. 1A;
the amino acid sequence shown in FIG. 1B; and
the amino acid sequence shown in FIG. 2.

### Claim 11

An isolated extracellular domain of Rse receptor protein tyrosine kinase (rPTK) essentially free of transmembrane and intracellular domains of full sequence Rse rPTK or an isolated extracellular domain of HPTK6 rPTK essentially free of transmembrane and intracellular domains of full sequence HPTK6 rPTK.

### Claim 12 (depends on 11)

The extracellular domain of Rse rPTK of claim 11, sharing at least 80% sequence identity with the translated extracellular domain of Rse rPTK shown in FIG. 1A.

### Claim 13 (depends on 12)

The extracellular domain of Rse rPTK as claimed in claim 12, sharing at least 90% sequence identity with the translated extracellular domain of Rse rPTK shown in FIG. 1A.

### Claim 14 (depends on 11)

The extracellular domain of HPTK6 rPTK of claim 11, sharing at least 80% sequence identity with the translated extracellular domain of HPTK6 rPTK shown in FIG. 2.

### Claim 15 (depends on 14)

The extracellular domain of HPTK6 rPTK of claim 14, sharing at least 90% sequence identity with the translated extracellular domain of HPTK6 rPTK shown in FIG. 2.

### Claim 16 (depends on 3)

A composition comprising the Rse rPTK of claim 3 and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 7)

A composition comprising the HPTK6 rPTK of claim 7 and a pharmaceutically acceptable carrier.

### Claim 18

An isolated ligand capable of binding Rse receptor protein tyrosine kinase (rPTK) or HPTK6 rPTK.

### Claim 19 (depends on 18)

The ligand of claim 18, wherein the ligand comprises a polyclonal antibody or a monoclonal antibody.

### Claim 20

An isolated Rse receptor protein tyrosine kinase (rPTK) or HPTK6 rPTK nucleic acid molecule.

### Claim 21 (depends on 20)

The isolated nucleic acid molecule of claim 20 having a nucleic acid sequence selected from the group consisting of:
(a) the nucleic acid sequence shown in FIG. 1A;
(b) the nucleic acid sequence shown in FIG. 1B;
(c) the nucleic acid sequence shown in FIG. 2;
(d) a sequence corresponding to the sequence of (a), (b) or (c) within the scope of degeneracy of the genetic code;
(e) a sequence which hybridizes with a sequence complementary to the sequence from (a), (b), (c) or (d) under stringent conditions and which codes for a receptor protein with tyrosine kinase activity.

### Claim 22

An isolated nucleic acid molecule encoding a ligand to Rse receptor protein tyrosine kinase (rPTK) or HPTK6 rPTK.

### Claim 23 (depends on 20)

A vector comprising the nucleic acid molecule of claim 20.

### Claim 24 (depends on 23)

A host cell comprising the vector of claim 23.

### Claim 25

A method for preparing Rse receptor protein tyrosine kinase (rPTK) or HPTK6 rPTK comprising culturing a host cell transfected to express Rse rPTK or HPTK6 rPTK nucleic acid and recovering the Rse rPTK or HPTK6 rPTK from the host cell culture.
